Former European bobsled champion Arran Gulliver has failed a doping test and been provisionally suspended, the International ...

IND submission is expected in the first half of 2026. A novel modified release oral formulation of enobosarm is under development and is projected to begin Phase 1 trials in the first half of 2025.

Veru's enobosarm is designed to be used in combination with GLP-1 agonist-based obesity drugs – such as Novo Nordisk's blockbuster Wegovy (semaglutide) – to reduce the loss of lean muscle mass ...

The company’s drug development program includes two late-stage novel small molecules, enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator (SARM), is being developed for ...

Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as greater ...

Stay updated on market trends for VERU. Veru Shares Tumble Despite Enobosarm's Lean Muscle Preservation Breakthrough Veru's enobosarm showed significant body composition benefits in Phase 2b ...

Detailed price information for Veru Inc (VERU-Q) from The Globe and Mail including charting and trades.